Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346747 · ClinicalTrials.gov registry record · Phase 2
A Trial of Vigil for Participants With Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Gradalis.
- Active
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT02346747 is a Phase 2 study of Ovarian Cancer and Ovarian Neoplasms that is active but no longer recruiting, run by Gradalis. The registered enrollment target is 92 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT02346747, a Phase 2 study of Ovarian Cancer and Ovarian Neoplasms, is active but no longer recruiting, sponsored by Gradalis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?"
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Vigil
Study Locations (20)
Florida
- University Of Miami Sylvester Comprehensive Cancer Center - Miami
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists - West Palm Beach
California
- Southern California Permanente Medical Group - Irvine
- Palo Alto Foundation Medical Group - San Francisco
Pennsylvania
- AMD Asplundh Cancer Pavilion - Abington
- St. Luke's Health Network - Bethlehem
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Georgia
- Georgia Cancer Center at Augusta University - Augusta
Kentucky
- University Of Kentucky Markey Cancer Center - Lexington
Maine
- Maine Medical Center: MMP Women's Health - Scarborough
Massachusetts
- Dana Farber Cancer Institute: Gynecologic Oncology - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-02 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346747
The ClinicalTrials.gov registry entry for NCT02346747 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02346747 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02346747 about?
NCT02346747 is a clinical study titled "A Trial of Vigil for Participants With Ovarian Cancer". The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to...
What is the current status of trial NCT02346747?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2015-02. Estimated completion is 2028-12.
What conditions does trial NCT02346747 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms.
What interventions are being tested in trial NCT02346747?
The interventions under investigation include: Placebo (OTHER), Vigil (BIOLOGICAL).
Who is sponsoring clinical trial NCT02346747?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02346747 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.